Embed Size (px)
DESCRIPTION
The 3rd Cell Line Development & Engineering Asia Conference is taking place on the 20 - 23 May 2014 at Grand Hyatt, Shanghai. A must attend event for you to get the latest updates and best practices in Cell Line Development & Engineering! A sneak peek at what’s NEW and EXCITING for 2014: Strategies in using omics to improve the structural quality of specific products Develop the right cell culture media and feeding strategies Get unpublished research updates on improving glycosylation and targeted integration Reduce timelines in your clone selection & screening process Get new approaches to optimize your transient expression system Visit http://www.celllineasia.com for more details.
Citation preview
www.celllineasia.com
Produced by: Associate Sponsor: Session Spotlight Sponsors: Exhibitors:
Associations:
REGISTER NOW! Customer Service Hotline: +65 6508 2401 / +86 21 2326 3680
International Marketing Partner:
Media Partners:
20 — 23 May 2014Grand Hyatt Shanghai, China
Accelerating Your Cell Line Development with Efficacy & Quality
THE 2014 NEW EXPERT FACULTY INCLUDES:
Dr Zhao (David)Xiao JianSenior Vice President &Chief Technology Officer,Wuhan YZYBiopharma, China
Dr H. Fai PoonDirector, Cell Culture,HisunPharmaceuticals,China
Dr Chengbin WuChief Scientific Officer &President of R&D,Shanghai CP GuojianPharmaceutical, China
Dr Qian Xue MingCEO & Chairman,MabspaceBiosciences, China
What’s New for 2014?New & Unpublished Data on TargetedIntegration, Glycosylation, Transient Expression& Clone Selection
Cell Line Development Strategies for Complex
Biologics
Achieve an Ideal Cell Culture Media for HighYield & Reproducibility
Navigate the Cell Line Regulatory Landscapefor Your Drug
Innovative Technology Showcase to Accelerate
your Cell Line Development Process
Pre-Conference Workshops: 20 May 2014
Optimizing Cell Culture Media Development & DesignStrategies
Cell Banking Management
Post-Conference Workshop: 23 May 2014
The Road to Commercialization: From Cell to MarketC
B
A
BIOBIOMANUFACTURINGBIOSIMILARSSIMILARSSIMILARSBIBI
ASIABI
Co-located with:
Part of
Bronze Sponsor:
PRODUCTION
BIOPHARMADEVELOPMENT &
WEEK
C LL LINEC LL LINEC LL LINEDEVELOPMENT &ENGINEERING ASIA
3RD ANNUAL
LifeSciences
REGISTER TODAY! +65 6508 2401 / +86 21 2326 3680 [email protected] www.celllineasia.com
BY INDUSTRY:■ Pharmaceuticals/Biotechnology: 50%
■ Research Institutes/Universities: 10%
■ CMOs: 20%
■ CROs: 10%
■ Technology Providers: 10%
BY REGION:■ China, Taiwan, Hong Kong: 60%
■ Japan, Korea: 10%
■ Rest of Asia: 10%
■ Europe: 10%
■ USA: 5%
■ Australia: 5%
Roche Diagnostics • Boehringer-Ingelheim • Genzyme • Sanofi • Shanghai Henlius Biotech • Eureka Therapeutics • Simcere • Luye Pharma • BTI A*Star •Neuclone • Wuhan YZY biopharma • Wuxi apptec • Fountain Biopharma • Novo Nordisk • Harbin Pharmaceutical Group • Genor Biopharma • TTY Biopharmcompany • JS Biosciences • Hisun Medicine • Genloci Biotechnologies • Shanghai Jiaotong University • University of Queensland • University ofManchester • Swiss Institute of Technology • John Hopkins University School of Medicine • National Health Research Institutes • Autekbio • Genescience• Dragonfly Sciences • Eli Lilly and Company • Hengru Medicine • TPG Biologics • Sinocelltech • Jiangsu Henrui Medicine • Egret Pharma Shanghai •Beijing Mabworks Biotech • Cbiopharm • Japan Asia Inestment (China) • 3SBIO • Jiangsu T-Mab Biopharma • SG Austria • Lonza Biologics • Tap biosystems• Sigma-Alrich • Genscript China • GE Healthcare AND MANY MORE...
Snapshot of Past Attending Companies Include:
The global cell culture market is expected to reach USD 16.85 billionglobally in 2018 (Transparency Market Research, 2013). However,the development of cell lines is still plagued with many challengesincluding quality, cost, timelines in the cell line development process,as well as titer. Due to the high cost of biologics production,strategies for cost-effective cell line development solutions to hastenthe drug into the market can ultimately lead to high profit margins.
IBC’s Cell Line Development & Engineering Asia brings togethertop experts and scientists from biopharma, biotechs, researchinstitutes, universities, CMOs and CROs as well as leading technologysolutions providers from all over Asia and the rest of the world.
It provides a platform where industry and research experts canshare research developments, case studies, best practices anddiscuss challenges pertaining to the cell line development industryto increase the efficacy and quality of cell lines for a faster, saferand more efficient biologics development process.
The Biopharma Development & Production Week is the leadingindustry platform for pharma, biotech, CMOs, CROs, research institutes,investors and industry stakeholders to meet, network and discusscurrent industry trends, establish business partnerships and beupdated on investment opportunities in China and surrounding Asia.
Co-Located with:
• Showcase the latest technology• Meet & Network with senior decision makers in Asia• Position your brand as the market leader to stand out amidst competition• Generate new business contacts and strengthen existing accounts
LIMITED SPONSORSHIP & EXHIBITION OPPORTUNITIES AVAILABLE:Do you provide innovative technology to support cell line development in Asia?
For sponsorship opportunities,contact Yvonne Leong atTel: +65 6508 2489Email: [email protected]
Who Should Attend:
Abundant Networking Opportunities withRegional & Global Companies!
BIOBIOMANUFACTURINGBIOSIMILARSSIMILARSSIMILARSBIBI
ASIABI
www.biosimilarsasia.com www.biomanufacturing-asia.com
About the BDP Week
Grow & BenchmarkYour Company Profilein the Cell Line Industry
Meet VIPGuests at
NetworkingLuncheons
Exchange BusinessCards & Get to Know
Your Peers in theShared Morning Ice
Breaker
Speed Networkingwith Pharmaceutical &
BiotechnologyCompanies
Shared NetworkingBreaks & Exhibition
Build LastingPartnerships &
Networks in a CasualNetworking
Evening Cocktail
20 — 23 May 2014Grand Hyatt Shanghai, China
Accelerating Your Cell Line Development with Efficacy & Quality
Part of
PRODUCTION
BIOPHARMADEVELOPMENT &
WEEK
C LL LINEC LL LINEC LL LINEDEVELOPMENT &ENGINEERING ASIA
3RD ANNUAL
![Clinical feasibility for cell therapy using human neuronal ... · Development of Human hNT2.17 Cell Line We subcloned a human neuronal cell line from the parental NT2 cell line [33]](https://img.dokumen.tips/doc/110x75/5e85441a5f8b2528e12f70b2/clinical-feasibility-for-cell-therapy-using-human-neuronal-development-of-human.jpg)
